(ZVRA) Zevra Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 617m USD | Total Return: 17% in 12m
Avg Turnover: 13.1M
Qual. Beats: 0
Rev. Trend: 94.2%
Qual. Beats: 2
Warnings
Altman Z'' -2.68 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Zevra Therapeutics, Inc. is a commercial-stage biotechnology firm specializing in treatments for rare diseases. The company utilizes its proprietary Ligand Activated Technology (LAT) platform to develop product candidates, including KP1077 for sleep disorders and Celiprolol for vascular Ehlers-Danlos syndrome. Its current commercial portfolio includes AZSTARYS for ADHD, OLPRUVA for urea cycle disorders, and MIPLYFFA for Niemann-Pick disease type C.
The company operates within the orphan drug sector, which often benefits from regulatory incentives such as extended market exclusivity and tax credits for clinical testing. Zevra’s business model relies on a mix of internal development and strategic licensing agreements with partners like Commave Therapeutics and Relief Therapeutics to manage manufacturing and global commercialization rights.
Investors may find additional insights on the companys valuation and long-term potential by reviewing the latest data on ValueRay. Formerly known as KemPharm, Inc., the company rebranded in 2023 and maintains its corporate headquarters in Boston, Massachusetts.
- Miplyffa commercial launch and market penetration drive long-term revenue growth
- Phase 3 clinical trial results for KP1077 determine future idiopathic hypersomnia valuation
- Azstarys royalty streams and milestone payments provide essential operational cash flow
- Regulatory approval and market entry for Celiprolol impact vascular Ehlers-Danlos expansion
- High research and development expenses necessitate strategic capital management for survival
| Net Income: 124.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 40.10 > 1.0 |
| NWC/Revenue: 149.6% < 20% (prev 134.5%; Δ 15.08% < -1%) |
| CFO/TA 0.05 > 3% & CFO 12.8m > Net Income 124.2m |
| Net Debt (-32.1m) to EBITDA (106.2m): -0.30 < 3 |
| Current Ratio: 4.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.2m) vs 12m ago 11.34% < -2% |
| Gross Margin: 85.51% > 18% (prev 0.79%; Δ 8.47k% > 0.5%) |
| Asset Turnover: 54.20% > 50% (prev 23.50%; Δ 30.69% > 0%) |
| Interest Coverage Ratio: 13.40 > 6 (EBITDA TTM 106.2m / Interest Expense TTM 7.72m) |
| A: 0.66 (Total Current Assets 230.0m - Total Current Liabilities 47.0m) / Total Assets 278.6m |
| B: -1.38 (Retained Earnings -384.2m / Total Assets 278.6m) |
| C: 0.46 (EBIT TTM 103.4m / Avg Total Assets 225.6m) |
| D: -5.30 (Book Value of Equity -386.0m / Total Liabilities 72.8m) |
| Altman-Z'' = -2.68 = D |
| DSRI: 0.58 (Receivables 22.1m/12.6m, Revenue 122.3m/40.6m) |
| GMI: 0.92 (GM 85.51% / 78.84%) |
| AQI: 0.33 (AQ_t 0.17 / AQ_t-1 0.52) |
| SGI: 3.01 (Revenue 122.3m / 40.6m) |
| TATA: 0.40 (NI 124.2m - CFO 12.8m) / TA 278.6m) |
| Beneish M = -1.98 (Cap -4..+1) = B |
As of May 24, 2026, the stock is trading at USD 10.49 with a total of 2,415,054 shares traded.
Over the past week, the price has changed by -8.90%,
over one month by -4.39%,
over three months by +15.29% and
over the past year by +17.04%.
Zevra Therapeutics has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy ZVRA.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 23 | 119.3% |
P/E Forward = 9.8814
P/S = 5.0419
P/B = 2.9959
P/EG = 10.6667
Revenue TTM = 122.3m USD
EBIT TTM = 103.4m USD
EBITDA TTM = 106.2m USD
Long Term Debt = 61.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 406k USD (from shortTermDebt, last quarter)
Debt = 63.5m USD (corrected: LT Debt 61.9m + ST Debt 406k) + Leases 1.15m
Net Debt = -32.1m USD (calculated: Debt 63.5m - CCE 95.6m)
Enterprise Value = 584.5m USD (616.6m + Debt 63.5m - CCE 95.6m)
Interest Coverage Ratio = 13.40 (Ebit TTM 103.4m / Interest Expense TTM 7.72m)
EV/FCF = 48.73x (Enterprise Value 584.5m / FCF TTM 12.0m)
FCF Yield = 2.05% (FCF TTM 12.0m / Enterprise Value 584.5m)
FCF Margin = 9.81% (FCF TTM 12.0m / Revenue TTM 122.3m)
Net Margin = 101.6% (Net Income TTM 124.2m / Revenue TTM 122.3m)
Gross Margin = 85.51% ((Revenue TTM 122.3m - Cost of Revenue TTM 17.7m) / Revenue TTM)
Gross Margin QoQ = 93.75% (prev none%)
Tobins Q-Ratio = 2.10 (Enterprise Value 584.5m / Total Assets 278.6m)
Interest Expense / Debt = 12.16% (Interest Expense 7.72m / Debt 63.5m)
Taxrate = 15.43% (6.91m / 44.8m)
NOPAT = 87.5m (EBIT 103.4m * (1 - 15.43%))
Current Ratio = 4.89 (Total Current Assets 230.0m / Total Current Liabilities 47.0m)
Debt / Equity = 0.31 (Debt 63.5m / totalStockholderEquity, last quarter 205.8m)
Debt / EBITDA = -0.30 (Net Debt -32.1m / EBITDA 106.2m)
Debt / FCF = -2.68 (Net Debt -32.1m / FCF TTM 12.0m)
Total Stockholder Equity = 152.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 55.05% (Net Income 124.2m / Total Assets 278.6m)
RoE = 23.14% (Net Income TTM 124.2m / Total Stockholder Equity 536.9m)
RoCE = 17.27% (EBIT 103.4m / Capital Employed (Equity 536.9m + L.T.Debt 61.9m))
RoIC = 37.71% (NOPAT 87.5m / Invested Capital 232.0m)
WACC = 7.44% (E(616.6m)/V(680.1m) * Re(7.15%) + D(63.5m)/V(680.1m) * Rd(12.16%) * (1-Tc(0.15)))
Discount Rate = 7.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 17.96%
[DCF] Terminal Value 75.44% ; FCFF base≈12.0m ; Y1≈12.0m ; Y5≈12.8m
[DCF] Fair Price = 3.90 (EV 198.4m - Net Debt -32.1m = Equity 230.6m / Shares 59.1m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.07 | # QB: 0
Revenue Correlation: 94.24 | Revenue CAGR: 147.2% | SUE: 1.61 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.17 | Chg30d=+51.65% | Revisions=-33% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.20 | Chg30d=+50.42% | Revisions=-20% | Analysts=4
EPS current Year (2026-12-31): EPS=1.17 | Chg30d=+134.74% | Revisions=+20% | GrowthEPS=-13.7% | GrowthRev=+38.6%
EPS next Year (2027-12-31): EPS=1.92 | Chg30d=+25.99% | Revisions=-33% | GrowthEPS=+64.4% | GrowthRev=+45.9%
[Analyst] Revisions Ratio: -33%